Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy–resistant human melanoma in IL2 transgenic NOD/SCID IL2 receptor knockout mice

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Elderly breast cancer patients benefit from surgery according to guidelines

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  2. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A large-cohort, longitudinal study determines pre-cancer disease routes across different cancer types

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Midkine-A potential therapeutic target in melanoma

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  • Elin Mv Forsberg
  • Mattias F Lindberg
  • Henrik Jespersen
  • Samuel Alsén
  • Roger Olofsson Bagge
  • Marco Donia
  • Inge Marie Svane
  • Ola Nilsson
  • Lars Ny
  • Lisa M Nilsson
  • Jonas A Nilsson
Vis graf over relationer

Chimeric antigen receptors (CAR) can transmit signals akin to those from activated T-cell receptors when bound to a cell surface target. CAR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use. However, no CAR-T therapy is currently approved for use in solid tumors. We hypothesize that the resistance of solid tumors to CAR-T can be overcome by similar means as those used to reactivate tumor-infiltrating T lymphocytes (TIL), for example, by cytokines or immune checkpoint blockade. Here we demonstrate that CAR-T cells directed against HER2 can kill uveal and cutaneous melanoma cells in vitro and in vivo. Curative effects in vivo were only observed in xenografts grown in a NOD/SCID IL2 receptor gamma (NOG) knockout mouse strain transgenic for human IL2. The effect was target-specific, as CRISPR/Cas9-mediated disruption of HER2 in the melanoma cells abrogated the killing effect of the CAR-T cells. The CAR-T cells were also able to kill melanoma cells from patients resistant to adoptive T-cell transfer (ACT) of autologous TILs. Thus, CAR-T therapy represents an option for patients that do not respond to immunotherapy with ACT of TIL or immune checkpoint blockade. In addition, our data highlight the use of IL2 transgenic NOG mice as models to prove efficacy of CAR-T-cell products, possibly even in a personalized manner. SIGNIFICANCE: These findings demonstrate that a novel humanized mouse model can help clinical translation of CAR-T cells against uveal and cutaneous melanoma that do not respond to TIL therapy or immune checkpoint blockade.

TidsskriftCancer Research
Udgave nummer5
Sider (fra-til)899-904
Antal sider6
StatusUdgivet - mar. 2019

ID: 56254105